首页> 美国卫生研究院文献>Pharmaceutics >In Vitro Release of Bioactive Bone Morphogenetic Proteins (GDF5 BB-1 and BMP-2) from a PLGA Fiber-Reinforced Brushite-Forming Calcium Phosphate Cement
【2h】

In Vitro Release of Bioactive Bone Morphogenetic Proteins (GDF5 BB-1 and BMP-2) from a PLGA Fiber-Reinforced Brushite-Forming Calcium Phosphate Cement

机译:从PLGA纤维增强的透钙磷石型磷酸钙水泥中体外释放生物活性骨形态发生蛋白(GDF5BB-1和BMP-2)。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Bone regeneration of sheep lumbar osteopenia is promoted by targeted delivery of bone morphogenetic proteins (BMPs) via a biodegradable, brushite-forming calcium-phosphate-cement (CPC) with stabilizing poly(l-lactide-co-glycolide) acid (PLGA) fibers. The present study sought to quantify the release and bioactivity of BMPs from a specific own CPC formulation successfully used in previous in vivo studies. CPC solid bodies with PLGA fibers (0%, 5%, 10%) containing increasing dosages of GDF5, BB-1, and BMP-2 (2 to 1000 µg/mL) were ground and extracted in phosphate-buffered saline (PBS) or pure sheep serum/cell culture medium containing 10% fetal calf serum (FCS; up to 30/31 days). Released BMPs were quantified by ELISA, bioactivity was determined via alkaline phosphatase (ALP) activity after 3-day exposure of different osteogenic cell lines (C2C12; C2C12BRlb with overexpressed BMP-receptor-1b; MCHT-1/26; ATDC-5) and via the influence of the extracts on the expression of osteogenic/chondrogenic genes and proteins in human adipose tissue-derived mesenchymal stem cells (hASCs). There was hardly any BMP release in PBS, whereas in medium + FCS or sheep serum the cumulative release over 30/31 days was 11–34% for GDF5 and 6–17% for BB-1; the release of BMP-2 over 14 days was 25.7%. Addition of 10% PLGA fibers significantly augmented the 14-day release of GDF5 and BMP-2 (to 22.6% and 43.7%, respectively), but not of BB-1 (13.2%). All BMPs proved to be bioactive, as demonstrated by increased ALP activity in several cell lines, with partial enhancement by 10% PLGA fibers, and by a specific, early regulation of osteogenic/chondrogenic genes and proteins in hASCs. Between 10% and 45% of bioactive BMPs were released in vitro from CPC + PLGA fibers over a time period of 14 days, providing a basis for estimating and tailoring therapeutically effective doses for experimental and human in vivo studies.
机译:通过具有可稳定降解的聚(l-丙交酯-乙交酯)酸(PLGA)纤维的可生物降解,形成透钙磷石的磷酸钙水泥(CPC)来定向递送骨形态发生蛋白(BMP),从而促进绵羊腰部骨质减少的骨再生。 。本研究试图量化BMPs从成功用于先前体内研究的特定自身CPC制剂的释放和生物活性。将含有PLGA纤维(0%,5%,10%)的GPC固体(含有增加剂量的GDF5,BB-1和BMP-2(2至1000 µg / mL))研磨,并在磷酸盐缓冲液(PBS)中提取或含有10%胎牛血清(FCS;长达30/31天)的纯羊血清/细胞培养基。通过ELISA定量释放的BMP,在不同成骨细胞系(C2C12; C2C12BRlb具有过表达的BMP-受体-1b; MCHT-1 / 26; ATDC-5)3天暴露后,通过碱性磷酸酶(ALP)活性确定生物活性。通过提取物对人脂肪组织间充质干细胞(hASCs)中成骨/软骨基因和蛋白质表达的影响。 PBS中几乎没有BMP释放,而在中等+ FCS或绵羊血清中,GDF5在30/31天内的累积释放为11–34%,BB-1在6–17%。 BMP-2在14天的释放率为25.7%。添加10%的PLGA纤维可显着增加GDF5和BMP-2的14天释放(分别达到22.6%和43.7%),但不增加BB-1的释放(13.2%)。事实证明,所有BMP都具有生物活性,这可以通过在几种细胞系中提高ALP活性,用10%PLGA纤维部分增强以及通过对hASC中成骨/成软骨基因和蛋白质的早期特异性调控来证明。在14天的时间内从CPC + PLGA纤维体外释放了10%至45%的生物活性BMP,为估算和调整实验和人体体内研究的治疗有效剂量提供了基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号